Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG7625 in Healthy Volunteers
NCT02295332Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of petesicatib in Sjögren's syndrome (2 cohorts), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events, laboratory abnormalities, changes in ECG, and vital signs at 22 weeks. Started Dec 2014; status: completed.
02
Drugs
petesicatib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT02295332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02295332.